期刊文献+

抗小鼠TLR-2胞外段B细胞识别表位抗体抑制肉瘤生长的初步研究 被引量:2

Inhibition of fibrosarcoma growth in mice by antibody against B cell epitope on mouse Toll-like receptor-2 extracellular domain
暂未订购
导出
摘要 目的观察抗小鼠TLR-2胞外段B细胞识别表位抗体对小鼠肉瘤S180生长的影响。方法在对小鼠Toll样受体2(mTLR-2)B细胞优势表位预测的基础上,合成B细胞识别表位20mer短肽,将其与载体蛋白偶联,制备免疫原。所得兔抗mTLR-2胞外段B细胞识别表位多克隆抗体TSP-1纯化后,采用Westernblotting、免疫组织化学和流式细胞仪进行初步鉴定。小鼠肉瘤株S180细胞注射小鼠左后肢,其中实验组混合100μg纯化抗体TSP-1,无关免疫球蛋白对照组混合100μg正常兔IgG,空白对照组仅接种S180。小鼠经麻醉分别于10、14、18d处死,称量瘤质量并计算抑瘤率。结果Westernblotting显示在相对分子质量约95000处可见清晰的反应条带;免疫组织化学和流式细胞术检测显示抗体可与表达天然mTLR-2的J774A.1细胞反应;实验组小鼠肉瘤生长明显受到抑制,其瘤质量在10、14、18d与对照组相比差异显著(P<0.05);抑瘤率分别为77%、51%和53%。结论局部应用抗mTLR-2胞外段B细胞识别表位抗体可抑制小鼠肉瘤S180生长,且表现在肿瘤生长的早期。 Objective To observe the effect of the antibody to a B cell epitope on mouse Toll-like receptor-2 (mTLR-2) extracellular domain on the growth of murine fibrosarcoma. Methods An immunogen was prepared by conjugating a 20-mer peptide, synthesized on the basis of prediction for B cell dominant epitope of mTLR-2, to a carrier protein. Rabbit polyclonal antibodies against B cell epitope of mTLR-2 were prepared and purified, and characterized by Western blotting, immunohisto- chemistry and flow cytometry. Murine fibrosarcoma S180 cells were inoculated into the left hindlimbs of Swiss mice, and in the treatment group, the injected cells were mixed with 100 γg anti-mTLR-2 antibody TSP-1, with the same dose of irrelevant rabbit IgG in the IgG control group and with buffer solution only in the blank control group. The mice in each group were anesthetized and sacrificed on days 10, 14, and 18 following the injections, respectively, and the weight of the tumors was measured and the inhibition rate calculated. Results A distinct band for the antibody TSP-1 was shown at the relative molecular mass of 95 000 by Western blotting. The antibody TSP-1 could also react with native mTLR-2 expressed on J774A.1 cells, as identified by immunohistochemistry and flow cytometry. The growth of the fibrosarcoma S180 was obviously inhibited by injections with the antibody TSP-1 mixture, and the weight of tumor in mice treated with TSP-1 was significantly lower than that in the two control groups (P<0.05), with an inhibition rate of 77% on day 10, 51% on day 14 and 53% on day 18. Conclusion Local application of the antibody against B cell epitope on mTLR-2 extracellular domain can inhibit the growth of murine fibrosarcoma, especially in the early stage of tumor proliferation.
出处 《第一军医大学学报》 CSCD 北大核心 2004年第8期873-876,共4页 Journal of First Military Medical University
基金 国家自然科学基金(30070719)~~
关键词 小鼠TLR-2 B细胞识别表位 抗体 肿瘤 murine Toll-like receptor 2 B cell epitope antibody tumor
  • 相关文献

参考文献11

  • 1Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens[J]. N Engl J Med, 1999, 340(23):1834-39.
  • 2Egil Lien, Timothy JS, Atsutoshi Y, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products[J]. J Biol Chem, 1999, 274(47): 33419-23.
  • 3刘艳君,富宁.广谱模式识别分子Toll-like receptor 2的研究进展[J].免疫学杂志,2002,18(3):234-236. 被引量:11
  • 4Okamoto M, Sato M. Toll-like receptor signaling in anti-cancer immunity[J]. J Med Invest, 2003, 50(1-2): 9-24.
  • 5Matsuguchi T, Takagi K, Musikacharoen T, et al. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes [J]. Blood, 2000, 95(4): 1378-85.
  • 6朱平,唐磊,赵善超,卢晓,候凡凡,富宁.抗人晚期糖基化终产物受体胞外段不同表位单克隆抗体的制备[J].第一军医大学学报,2004,24(2):129-132. 被引量:6
  • 7朱国鸿,刘北一,郑山根,吕海,史占军.骨肉瘤细胞特异性结合短肽的筛选[J].第一军医大学学报,2003,23(1):12-15. 被引量:2
  • 8Wetzler LM. The role of Toll-like receptor 2 in microbial disease and immunity[J]. Vaccine, 2003, 21 (S2): 55-60.
  • 9Seya T, Akazawa T, Uehori J, et al. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer [ J ]. Anticancer Res, 2003, 23(6a): 4369-76.
  • 10Oshikawa T, Okamoto M, Ohe G, et al. Anti-rumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding [J]. Int Immunopharmacol, 2003, 3(5): 643-55.

二级参考文献20

  • 1[1]Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues[J]. Am J Pathol, 1993, 143(6): 1699-712.
  • 2[2]Hori O, Yan SD, Ogawa S, et al. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus [J]. Nephrol Dial Transplant, 1996,11 (Suppl 5):13-6.
  • 3[3]Miyata T, Hori O, Zhang J, e t al Thereceptor for advaneed glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2 microglobulin with human mononucleεr phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis [J ]. J Clin Invest, 1996, 98(5): 1088-94.
  • 4[4]Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer'sdisease [J]. Brain Res, 2001, 888 (2):256-62.
  • 5[5]Chappey O, Dosquet C, Wautier MP, et al. Advanced glycation end products, oxidant stress and vascular lesions[ J ]. Eur J Clin Invest,1997, 27(2): 97-108.
  • 6[6]Hsieh HL, Schafer BW, Sasaki N, et al. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays [ J ].Biochem Biophys Res Commun, 2003, 307(2): 375-81.
  • 7[7]Ishihara K, Tsutsumi K, Kawane S, et al. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site[J]. FEBS Lett, 2003, 550(1-3): 107-13.
  • 8[8]Hou FF, Chertow GM, Kay J, et al. Interaction between β 2m and AGE in the development of dialysis-related amyloidnsis[J]. Kidney Int, 1997, 51(5): 1514-9.
  • 9[9]Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy, soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rat[J]. J Clin Invest, 1996, 97(1): 238-43.
  • 10Sato S,Nomura F,Kawai T,et al.Synergy and cross-tole-rance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways[].J Immunol.2000

共引文献16

同被引文献21

  • 1Merrel MA,Ilvesaro JM,Lehtonen N,et al.Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity[J].Mol Cancer Res,2006,4(7):437-447.
  • 2Szczepanski M,Stelmachowska M,Stryczynski L,et al.Assessment of expression of toll-like receptors 2,3 and 4 in laryngeal carcinoma[J].Eur Arch Otorhinolaryngol,2007,264(5):525-530.
  • 3Huang B,Zhao J,Shen S,et al.Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signalling[J].Cancer Res,2007,67(9):4346-4352.
  • 4Chang YJ,Wu MS,Lin JT,et al.Induction of Cyclooxygenase-2 Overexpression in Human Gastric Epithelial Cells by Helicobacter pylori Involves TLR2/TLR9 and c-Src-Dependent Nuclear Factor-κB Activation[J].Mol Pharmaco,2004,l66(6):1465-1477.
  • 5Yoshioka T,MorimotoY,Iwagaki H,et al.Bacterial lipopolysaccharide induces transforming growth factor beta and hepatocyte growth factor through toll-like receptor 2 in cultured human colon cancer cells[J].J Int Med Res,2001,29(5):409-420.
  • 6Suh J,Rabson AB.NF-kB activation in human prostate cancer:important mediator or epiphenomenon[J] ? J Cell Biochem,2004,91(1):100-117.
  • 7Karin M,Cao Y,Greten FR,et al.NF-kB in cancer:from innocent bystander to major culprit[J].Nat Rev Cancer,2002,2(4):301-310.
  • 8Helbig G,Christopherson KW,Bhat-Nakshatri P,et al.NF-kB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4[J].J Biol Chem,2003,278(24):21631-21638.
  • 9Tabeta,K,George P,Janssen E,et al.TLR9 and TLR3 as essential components of innate immune defense against mouse cytomegalovirus[J].Proc Natl Acad Sci USA,2004,101(10):3516-3521.
  • 10Huang B,Zhao J,Li HX,et al.Toll-like receptors on tumor cells facilitate evasion of immune surveillance[J].Cancer Res,2005,65(12):5009-5014.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部